Australia drugmaker Mayne Pharma Group and privately held Prasco Laboratories have emerged as the latest winners in the Teva Pharmaceutical -Allergan generics divestiture process. Adelaide, Australia -based Mayne said in a June 28 announcement that that it will pay $652 million in cash for 37 approved and five FDA-filed products from Teva and Allergan.